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Background: We studied a family including two half-siblings, sharing the same mother, affected by slowly
progressive, adult-onset neurological syndromes. In spite of the diversity of the clinical features, characterized by a
mild movement disorder with cognitive impairment in the elder patient, and severe motor-neuron disease (MND)
in her half-brother, the brain Magnetic Resonance Imaging (MRI) features were compatible with adult-onset
Alexander’s disease (AOAD), suggesting different expression of the same, genetically determined, condition.
Methods: Since mutations in the alpha isoform of glial fibrillary acidic protein, GFAP-α, the only cause so far known
of AOAD, were excluded, we applied exome Next Generation Sequencing (NGS) to identify gene variants, which
were then functionally validated by molecular characterization of recombinant and patient-derived cells.
Results: Exome-NGS revealed a mutation in a previously neglected GFAP isoform, GFAP-ε, which disrupts the
GFAP-associated filamentous cytoskeletal meshwork of astrocytoma cells. To shed light on the different clinical
features in the two patients, we sought for variants in other genes. The male patient had a mutation, absent in his
half-sister, in X-linked histone deacetylase 6, a candidate MND susceptibility gene.
Conclusions: Exome-NGS is an unbiased approach that not only helps identify new disease genes, but may also
contribute to elucidate phenotypic expression.Background
Alexander’s disease (AD, OMIM #203450) is a rare
neurological disorder characterized by a peculiar form of
leukodystrophy, with infantile, juvenile and adult forms
manifesting with different clinical and pathological signs
[1]. AD is a sporadic or autosomal dominant condition
associated in most of the cases with heterozygous muta-
tions in the gene encoding the glial fibrillary acidic pro-
tein, GFAP, an intermediate filament component of the
cytoskeleton of several cell types [2]. GFAP mutations
frequently occur de novo, particularly in infantile cases,* Correspondence: zeviani@istituto-besta.it
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distribution, and reproduction in any mediumwhile in Adult-onset AD (AOAD) both de novo muta-
tions and autosomal dominant transmission have been
described [3]. GFAP-containing eosinophil aggregates,
known as Rosenthal fibers, distributed in the white mat-
ter of the CNS, constitute the morphological hallmark of
the disease [2]. Whilst the infantile form shows extensive
white matter lesions and usually fatal outcome, AOAD
is characterized by predominant brainstem involvement
and survival into adulthood [4].
We here report the results of exome next-generation
DNA sequencing (NGS) conducted on a family with two
maternal half-siblings, affected by two distinct adult-
onset neurological syndromes: mild cognitive deterior-
ation and movement disorder in a female patient,
motor-neuron disease (MND) in her half-brother. Thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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unrelated fathers, suggesting either an X-linked or an
autosomal dominant condition with variable penetrance
and expressivity. In spite of the diversity of the clinical
features, the brain MRI features were compatible with
AOAD. However, standard sequence analysis of the nine
canonical exons encoding the predominant isoform,
GFAP-α, had previously ruled out mutations in both
patients.
NGS is a holistic, unbiased approach that generates
comprehensive information on gene variance [5]. Exome
NGS analysis in our family revealed a heterozygous mis-
sense mutation in an alternative exon of the GFAP gene
(exon 7A), which has not previously been included in
the diagnostic screening of AOAD. Additional variants
in other genes included a private mutation in the
X-linked gene encoding histone deacetylase 6, HDAC6,
which was present in the male, but absent in the female,
patients. HDAC6 was suggested to have a modulating
role in different processes related to neurodegeneration, in-
cluding authophagy, proteosomal degradation, aggresomeFigure 1 Pedigree and radiological features of the patients. A: Pedigre
Pt2). Genotypes of each tested individual are indicated under the correspo
mutant). I-3 died of colon cancer at 62 years of age; I-1died of unknown ca
age. B: Brain MRI findings of Pt1 (a-f) and Pt2 (g). Atrophy of the medulla is
lemniscus (a, arrows). In the cerebellum, the hylum of the dentate nucleus
substantia nigra and medial lemniscus are hyperintense (b, arrows); a sub-p
Symmetrical signal abnormalities involve the pallida, particularly at the inte
Hyperintensitiy is present in the periventricular white matter, pre- and post
(f, arrows). The typical tadpole appearance of the brainstem and cervical spformation [6,7]. We demonstrated that the mutant HDAC6
variant has reduced deacetylase activity, which could
contribute to the different phenotypes of our patients.
Patients and methods
Case reports
Patient 1, Pt1 (subject II-2 in Figure 1A) is now 68 years
old. Her insidious disease onset started at 55 years, and
was first characterized by psychiatric symptoms, initially
as a bipolar disorder with depression alternated by hypo-
manic behavior (compulsive gambling), and eventually
as a cognitive deterioration with apathy, neglect of per-
sonal care, and memory loss. Shortly thereafter, she
manifested an ataxic gait with frequent falls, followed by
progressive dysarthria, dysphagia to liquids, drooling,
and fluctuating palatal myoclonus. An Electroencephal-
ography at 61 showed unspecific irritative abnormalities;
visual evoked potentials were altered. The neurological
examination disclosed a moderate ataxic gait requiring a
can, dysarthria, palatal myoclonus, and hypotonia (right >
left), increased tendon reflexes, a positive Babinski sign ate of the family. Black symbols indicate affected patients 1 and 2 (Pt1,
nding symbols (GFAP G: wt; GFAP A: mutant; HDAC6 C: wt; HDAC6 T:
uses when he was over 80; II-3 died of a cerebral stroke at 60 years of
present, with signal abnormalities of the pyramidal tract and medial
is bilaterally hyperintense (a, thick arrows). At midbrain level (b,c),
ial rim of high signal intensity is present in the FLAIR image (c).
rface with the posterior limb of the internal capsule (d, arrows).
-central gyri (e, arrows on the right) and subcortical frontobasal areas
inal cord is seen in the midline sagittal section of Pt2 (g).
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movements were normal. A Mini Mental State Examin-
ation scored 16/30. The syndrome slowly progressed, with
worsening of cognitive deterioration, dysarthria and
dysphagia, and onset of urinary incontinence. Several
Electromyography (EMG) examinations have consistently
been normal over time.
Pt2 (II-4 in Figure 1A), now 60 years old, was first re-
ferred to us at 52, for insidiously progressive walking
difficulties, initiated at 46 years with stiffness and weak-
ness at the right lower limb, followed within 3-5 years
by involvement of the right upper, and then left lower
and upper limbs. He also reported symptoms consistent
with nocturnal lower-limb myoclonus. The neurological
examination at 52 years showed spastic tetraparesis,
more prominent on the right side and lower limbs, bilat-
eral pes equinovarus, normal strength, bilateral Babinski
sign. His gait was paraparetic with bilateral thigh adduc-
tion; however he could still walk unassisted. He showed
no muscle wasting, with the exception of bilateral atro-
phy of the temporalis muscle. He was diagnosed as hav-
ing “primary lateral sclerosis” and started riluzole and
baclofen, with no tangible benefit. Over the subsequent
two years he developed mild spastic hypophonia, and
moderate dysphagia for liquids, with worsening of the
limb spasticity. At 56 he became wheelchair-bound,
severely dysphonic and dysphagic, with severe tetra-
spasticity, flexed posture, bilateral ankle clonus, bilateral
Babinski, bilateral hypotrophy of temporalis, interosseus
and tibialis anterior muscles. Sensory examination and
neurovegetative tests were normal, as were the eye
movements. The EMG showed neurogenic abnormal-
ities, without spontaneous fibrillation. Nerve conduction
studies showed motor axonal neuropathy at the lower
limbs, whereas the peripheral sensory conduction was
normal. Taken together, these findings indicate severe
motor-neuron disease (MND) of limb and bulbar dis-
tricts. Symptoms have slowly progressed over time. The
patient has no cognitive deterioration.
The MRI findings of these patients were very similar
and consistent with the diagnosis of AOAD (Figure 1B).
Atrophy of the medulla oblongata and cervical spinal
cord (“tadpole” appearance) and signal abnormalities
were present in the brainstem, dentate nuclei and
supratentorial periventricular white matter. Additional
findings, peculiar to our patients, were mild atrophy of
the midbrain with T2 hyperintensity of the substantia
nigra and medial lemniscus, pallida, and subcortical
white matter in the pre- and post-central gyri and
frontobasal areas. Interestingly, Pt1, who had more
marked cognitive impairment, had slightly more exten-
sive supratentorial white matter involvement.
To quantitatively express the different clinical features
of the two siblings, we used the Kurtzke scale [8](Additional file 1), that scores several functional systems
(motor, cerebellar, brainstem, urinary, visual, and cogni-
tive) usually involved in white matter disease, including
leukodystrophies. The scores were obtained 13 years
after disease onset for Pt1 and 14 years after onset for
Pt2. The global functional impairment, as assessed by
the final EDSS score, [9] was 3/10 for Pt1 (able to walk,
moderate ataxia and cognitive impairment, not requiring
institutionalization) and 8.5/10 for Pt2 (confined to bed
but with some residual upper limb function). For Pt2,
the source of the severe disability was predominantly
due to pyramidal dysfunction: we thus assessed both
patients by also using the ALS-Severity scale, [10] which
scored 33/40 for pt1 (speech 7, deglutition 6, upper
limbs 10, lower limbs 10), and 17/40 for pt2 (speech 3,
deglutition 8, upper limbs 4, lower limbs 2). The results
of instrumental examinations are reported in Table 1.
Molecular analyses
Informed consent for participation in this study was
obtained from all family members, in agreement with
the Declaration of Helsinki and approved by the Ethical
Committee of the Fondazione Istituto Neurologico –
IRCCS, Milan, Italy.
Genomic DNA was extracted by standard methods from
peripheral blood samples (I-2, II-2, II-4, II-6, II-7, III-1,
III-3) and from skin fibroblasts (II-2, II-4). Whole-exome
and Sanger’s sequencing were performed as described [11].
Total RNA was isolated from fibroblasts (RNeasy kit,
Qiagen) and then transcribed to cDNA (Cloned AMV
first-strand cDNA synthesis kit, Invitrogen). Quantitative
Real-time PCR (QRtPCR) was assayed on an ABI Prism
7000 apparatus (Applied Biosystems). Additional file 2
reports primers and conditions for PCR amplifications of
relevant exons of human GFAP and HDAC6 and for
QRtPCR of HDAC6 cDNA.
Additional file 3 reports URLs for biocomputational
analysis.
A GFP tagged GFAP cDNA (Origene RG225707) was
modified by using Quick-change Site-directed mutagen-
esis kit (Stratagene) to introduce either the c.1289G > A
or the c.1288C > T nucleotide change in the RG225707
clone, using primers listed in Additional file 2.
Cellular experiments
Cell culture, transient transfections, western-blot ana-
lysis, and immunocytochemistry were performed as de-
scribed, [12-15] using antibodies against α-tubulin
(Life Science) and acetylated α-tubulin (Sigma). Pa-
tients’ fibroblasts and adult control fibroblasts were
grown under the same conditions, and analyzed among
culture passages 5 and 8. As a positive control for
tubulin acetylation, fibroblasts were pre-incubated
with the specific HDAC6 inhibitor Tubacin (0, 0.2 μM
Table 1 Clinical and instrumental assessments
Pt1 Pt2
Current age 68 60
Age at onset 55 46
Disease duration at the time of examinations, years 13 14
Instrumental assessment *
Cognitive: MMSE score 16/30 30/30
EMG 0 Mild motor axonal neuropathy (1)
MEPs Bulbar/UL/LL N.A./0/0 1/1/3
SEPs UL/LL 1/1 0/1
BAEPs NA NA
VEPs 0 0
Autonomic testing 0 0
Clinical scoring **
Dysarthria/dysphagia 2 2
Gait abnormalities 1 3
Spasticity 0 3
Axial Ataxia 1 0
Limb dysmetria 2 0
Limb weakness 0 2
Muscle wasting 0 1
Sphincter function 2 0
* For neurophysiological assessments, values are graded as 0 (normal), 1 (abnormality not exceeding 25% of upper/lower normal ranges), 2 (between 25 and
50%), and 3 (beyond 50%).
** For clinical dysfunctions, abnormalities are graded as 0 (normal), 1 (only objective signs), 2 (mild dysfunction, not interfering with activities), 3 (severe
dysfunction interfering with walking, feeding, or social interactions).
MMSE: mini–mental state examination; EMG: Electromyography; MEPs: Motor evoked potentials; SEPs: Sensory evoked potentials; UL/LL: upper/lower limbs; BAEPs:
Brainstem Auditory Evoked Potentials; VEPs: visual evoked potentials.
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istry was carried out on 2 μm thick sections from pel-
lets of Pt1, Pt2 and control fibroblasts, fixed in
glutaraldehyde 2.5% (Electron Microscopy Science -
EMS), in 0.05 M PBS pH 7.4, dehydrated in graded
acetone, and embedded in Spurr (Epoxy resin, EMS).
Transfection of U251-MG by electroporation was
performed in triplicate according to the manufacturer’s
protocol (GenePulserII-Biorad), and about 100 cells were
analyzed blindly for each experiment (a total of 324 cells
for GFP-GFAP-εwt and 285 for GFP-GFAP-εR430H in a
first experiment, and 460 cells for either GFP-GFAP-εwt
or GFP-GFAP-εR430C in a second experiment).Results
Mutational screening ruled out mutations in the SPG4
and SPG7 genes in Pt2, due to the presence of spastic
tetraparaparesis; in the HTT gene in Pt1, due to the sub-
tle onset of symptoms consistent with an affective dis-
order, together with cognitive dysfunction; and in the
UBQLN2 and C9orf72 genes, recently associated to
ALS/FTD, in both.The MRI features were consistent with AOAD, but
no mutation was detected in the nine exons encoding
the prevalent (alpha) isoform of GFAP (GFAP-α,
NP_002046.1; Figure 2A). All of the known mutations
associated with Alexander’s disease have so far been
found in this isoform, [17] which is the only one ana-
lyzed by standard screening. However, exome-NGS re-
vealed a heterozygous variant (c.1289G > A, p.R430H) in
the alternative GFAP exon 7A (Ex7A) in both patients
(Figure 2B). Ex7A is part of the transcript encoding the
GFAP-ε isoform (NP_001124491.1), which differs from
GFAP-α in the last 35 amino acids. A third isoform,
GFAP-κ (NP_001229305.1), which contains a unique
exon 7B, has also been identified (Figure 2A) [18]. The
c.1289G>A nucleotide change was absent in the healthy
mother and in all other tested family members. DNA
samples from I-1 and I-3, fathers of Pt1 and Pt2, respect-
ively, were unavailable. Haplotype analysis of the GFAP
genomic region by SNPs array in the available family
members confirmed that the father of Pt1 was different
from that of Pt2 and of his siblings, whilst Pt1 and Pt2
share the same maternal allele (Additional file 4). Since
the likelihood that the same rare variant (<0.01%) may
Figure 2 Characterization of the GFAP c.1289G>A/p.R430H mutation. A: Schematic representation of the exonic structure of different GFAP
isoforms. Dotted lines indicate the termination codons. The arrows indicate the position of the c.1289G>A variant (Note that in GFAP-κ the
c.1289G>A mutation is part of the 3′-UTR). B: Electropherograms of GFAP exon 7A region containing c.1289G>A variant, in patients 1 and 2 (Pt1,
Pt2) and in their mother (I-2). C: The histogram displays the percentages of cells transfected with GFP-GFAP-εwt (green bars) or GFP-GFAP-εR430H
(purple bars), classified in filamentous pattern (F), cytoplasmic aggregates on a filamentous pattern (F + A), cytoplasmic aggregates with no
filamentous pattern (A). Scale bars represent 15 μm. A total of 324 cells for GFP-GFAP-εwt and 285 for GFP-GFAP-εR430H, from 3 independent
experiments, were blindly analyzed by two different operators. ANOVA test for interaction p = 0.001.
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most probable hypothesis is that the mutation was trans-
mitted by descent to both Pt1 and Pt2 by maternal ger-
minal mosaicism, a mechanism that can also explain the
healthy status of the mother. Since blood was the only
source of DNA available from the mother, somatic mo-
saicism affecting other tissues of this subject cannot be
excluded, as recently found in an AD patient with atyp-
ical infantile clinical presentation and essentially normal
MRI features [19]. However, we think that the latter hy-
pothesis is unlikely, since no trace of mutation could be
detected by an ad hoc RFLP analysis carried out in the
mother’s DNA (not shown) and, in contrast with the
case reported by Flint et al. [19], this lady is now 87
years old and well.
In contrast with a p.R430C SNP (rs 78994946), reported
with a frequency of 1% in dbSNP, the p.R430H change
found in our patients is absent in both dbSNP and the
Exome Variant Server (EVS) database, which contains
>10000 alleles (≈7000 of European origin). These data are
compatible for p.R430H being a deleterious mutation
(Additional file 5).
GFAP is an intermediate filament (IF) protein expressed
mainly by astrocytes and ependymocytes. Recent data sug-
gested that GFAP-ε was unable to form filaments by itself
but it could participate to the formation of the GFAP net-
work by interacting with GFAP-α [20]. Hence we analyzed
the IF meshwork in human astrocytoma U251-MG cells,
constitutively expressing both GFAP-α and GFAP-ε, by
expressing GFP-tagged wt and mutated GFAP-ε (GFP-
GFAP-εwt vs. GFP-GFAP-εR430H). Cells were assigned to
three patterns: [14] (i) exclusively filamentous pattern (F),(ii) cytoplasmic aggregates on a filamentous pattern (F +A),
(iii) cytoplasmic aggregates with no filamentous pattern
(A). The expression of GFP-GFAP-εwt led to a distribution
among the three groups similar to that reported for
GFP-GFAP-αwt [14] (Figure 2C) indicating no intrinsic
damaging effect of recombinant GFP-GFAP-εwt in our ex-
perimental conditions. Contrariwise, expression of mutant
GFP-GFAP-εR430H produced significant decrease in F (43%
vs. 58%; test t p = 0.002) and increase in A (22% vs. 15%;
test t p = 0.009) cells (Figure 2C), with a distinct distribu-
tion in the three patterns compared to GFP-GFAP-εwt ex-
pressing cells (ANOVA test for interaction p = 0.001).
Notably, the expression of GFP-tagged GFAP carrying the
R430C variant (GFP-GFAP-εR430C) led to a distribution
amongst the three different patterns similar to that
obtained with GFP-GFAP-εwt, i.e. non-significant (ANOVA
test for interaction p = 0.333). These results indicate that
GFAP-εR430H is inefficiently incorporated, and is likely to
perturb the GFAP network in GFAP-expressing astrocy-
toma cells, whereas the GFAP-εR430C variant is functionally
wt, but we cannot exclude the possibility that variations in
the level of expression contributed to this result.
To test whether additional genes could influence
phenotype expression, 18 genes with variants in Pt2
were prioritized by the Endeavour software, [21] using
“training genes” associated with MND (Additional
file 6). The highest score was achieved by HDAC6, on
chromosome Xp11.23, encoding a member of the his-
tone deacetylase family (NP_006035.2); Pt2 was hemi-
zygous for a c. 2566C>T/p.P856S, variant, whereas Pt1,
II-6 and II-7 were wt, and the mother, I-2, was hetero-
zygous (Figure 3A). Whilst the variants in the other
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also in Pt1 (Additional file 6), the P856S change was
absent in all available databases, including EVS. The
amount of HDAC6 transcripts was similar in fibro-
blasts from Pt2 vs. Pt1 or control subjects, indicating
that neither HDAC6 expression nor stability is severly
affected by the mutation (Figure 3B). However, acety-
lated alpha-tubulin, a HDAC6 substrate, [22] was
consistently increased (Figure 3C); treatment of fibro-
blasts with tubacin, a selective HDAC6 inhibitor,
clearly increased the acetylation of alpha-tubulin,Figure 3 Characterization of the HDAC6 c.2566C>T/p.P856S variant. A
c.2566C>T variant, in patients 1 and 2 (Pt1, Pt2) and their mother (I-2). B: Le
GAPDH cDNA, in controls (Ct; mean of five subjects) and patients 1 and 2 (
Student’s t-tests showed no significant differences: Pt2 vs. Ct p = 0.811; Pt2
analysis of fibroblast lysates from control subjects (Ct1, Ct2) and patients 1
panel), α-tubulin (middle panel) and α-GAPDH, as loading control (lower pa
obtained by densitometric analysis from 3 independent experiments: 100%
Student’s t-test Pt2 vs Ct p = 0.002, Pt1 vs Ct p = 0.33. D: Immunocytochem
(Pt1, Pt2), using antibodies against α-tubulin and acetylated α-tubulin. Scale
multilobated nuclei in control, Patient1 and Patient2. A total of 15 digital im
sections were collected and analyzed for each sample; the arrow indicates
Control vs. Pt1 showed no significant differences (p = 0.4970); Pt2 vs. Contrconfirming the specificity of this assay to detect im-
paired HDAC6 activity (Additional file 7).
Densitometric analysis of immunoreactive bands from
three independent experiments, showed that the ratio
acetylated α-tubulin/α-tubulin was significantly aug-
mented to 213% in Pt2, compared to the mean value of
four control subjects, but was unchanged (87%) in Pt1
(Figure 3C). Moreover, immunocytochemical staining
showed abnormal clumps of acetylated α-tubulin in the
perinuclear region of Pt2 fibroblasts (Figure 3D). Inter-
estingly HDAC6P856S fibroblasts showed a significantly: Electropherograms of HDAC6 exon 25 region containing the
vels of HDAC6 transcript, normalized to that of the endogenous
Pt1, Pt2), obtained from 3 independent experiments. Two-tailed
vs. Pt1 p = 0.813; Pt1 vs. Ct p = 0.896. C: Exemplifying Western-blot
and 2 (Pt1, Pt2), using antibodies against acetylated α-tubulin (upper
nel). The graph represents the ratio acetylated α-tubulin/α-tubulin
corresponds to the mean value of four control subjects. Two-tailed
istry on fibroblasts from a control subject (Ct) and patients 1 and 2
bars are reported on the right for each row. E: Percentages of
ages (at least 600 cells for each patient) representative of the whole
a typical multilobated nucleus. Two-tailed Student’s t-test between
ol p = 0.000099; Pt2 vs. Pt1 p = 0.000018 (both highly significant).
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trol cells, which could be consequent to altered physical
connection between nuclear membrane and cytoskeletal
network (Figure 3E). Taken together these results sug-
gest dysregulation of the microtubule-organizing center
(MTOC), associated with reduced HDAC6 activity [23].
Discussion
A substantial fraction of AOAD patients are sporadic,
the most frequent symptoms being related to bulbar dys-
function, pyramidal involvement and cerebellar ataxia.
Palatal myoclonus is frequent in, and highly suggestive
of, AOAD [4]. Other findings include cognitive deterior-
ation, sleep disorders, and dysautonomia. The course is
slowly progressive and fluctuations may occur. Ultim-
ately, the diagnosis is strongly suggested by a typical
MRI pattern, and confirmed by GFAP gene analysis. In
our family, Pt1 has been suffering of slowly progressive
cognitive impairment and mild movement disorder,
whereas her younger half-brother (Pt2) has severe MND.
In spite of clinical diversity, the cardinal MRI features of
AOAD [24] were present in both. The absence of muta-
tion in the GFAP-α encoding gene prompted us to
perform exome-NGS and eventually identify a unique
mutation in alternative GFAP ex7A, not present in the
healthy mother tested DNAs and with a deleterious
outcome in a cellular model. These are in fact the first
cases associated with a mutation in the GFAP-ε variant
(GFAP-εR430H). Whilst this finding supports the idea that
AOAD is almost invariably associated with abnormalities
of GFAP, it also expands the spectrum of variants that
should be included in the diagnostic screening. Due to
the pedigree structure, the mutation has very likely been
transmitted by maternal germinal mosaicism, since it
was absent in other available family members, including
the healthy mother of the two patients.
The clinical diversity in our two half-siblings was as re-
markable as to suggest that differential segregation of other
gene variants could influence phenotypic expression. A pri-
oritized variant found by in-silico data mining was in
HDAC6. A hemizygous HDAC6P856S change, found in Pt2,
and absent in Pt1, was associated with decreased tubulin-
specific deacetylase activity [22]. Through deacetylation of
α-tubulin, HSP90, and other substrates, and binding to
ubiquitinated proteins that are then transported into, and
degraded by, the aggresome, HDAC6 plays a role in a num-
ber of important homeostatic and signaling pathways,
including axonal transport, redox signaling, misfolded-
protein response, and autophagy [25,26]. Interestingly, the
RNA-binding modulator factors TDP-43 and FUS/TLS,
whose mutations are associated with familial amyotrophic
lateral sclerosis (ALS), have HDAC6 mRNA as a specific
substrate [27]. A Drosophila model in which TDP-43 is si-
lenced shows decreased HDAC6 expression, [28] andHDAC6 overexpression is able to rescue the phenotype of a
Drosophila model of spinobulbar muscular atrophy [6].
Taken together, these observations indicate HDAC6 as
a master regulator of different neuroprotective mecha-
nisms, partly mediated by controlling MTOC biogenesis
and function, [23] and predict a role for defective
HDAC6 in neurodegeneration, particularly in MND
[26]. As for mammalian models, although a first strain
of HDAC6 knockout (KO) mice presented no sign of
neurodegeneration, [29] altered emotional behaviors
suggested a contribution of HDAC6 to maintain proper
neuronal activity [30]. Moreover, a second KO HDAC6
strain displayed ubiquitin-positive aggregates and increased
apoptosis of brain nerve cells, both hallmarks of
neurodegeneration, starting from 6 months of age [31].
These and other results suggest for HDAC6 a complex
role in contributing to either neuroprotection or
neurodegeneration, depending on the specific pathological
condition [7,26,32]. These opposite effects can indeed
hamper the development of therapeutic strategies based
on HDAC6 modulation [7].
Albeit preliminary, our own results support the inter-
esting hypothesis that the HDAC6P856S protein variant
may be acting synergistically with the GFAP-εR430H mu-
tation, conditioning the development of the severe MND
phenotype of Pt2.
The mechanisms underlying the diverse etiology and
expressivity of many inherited neurodegenerative disor-
ders are still poorly understood. Exome-NGS is an
unbiased approach that not only helps identify new
disease genes, but may also contribute to elucidate
phenotypic expression and penetrance.
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